Breast Cancer in SCD Patient: A Case Report and Literature Review

Full Article - PDF

Published: 2023-06-03

Page: 15-19


Entisar Al-Zaman

Department of Obstetrics and Gynecology, Salmaniya Medical Complex, Kingdom of Bahrain.

Aysha S. Al-Zaman *

Department of Hematology-Oncology, Salmaniya Medical Complex, Kingdom of Bahrain.

Yahya Al-Zaman

Department of Endocrinology and Internal Medicine, Bahrain Defense Force Hospital, Kingdom of Bahrain.

*Author to whom correspondence should be addressed.


Abstract

Background: Malignancies have been often reported among patients with sickle cell disease (SCD), with breast cancer being the most common cancer among females. However, the data available so far in the literature on the safety of oncological treatments in patients with sickle cell disease (SCD) especially that they are more prone to develop serious and even life-threatening treatment-related complications, is very limited.

Case report: Here, we report a case of a 48-year-woman with SCD who presented with metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer and was treated accordingly with 3 weekly pertuzumab, trastuzumab anti-HER2 monoclonal antibodies and weekly paclitaxel 80 mg/m2 days one, eight, and 15 as per the standard regimen for metastatic breast cancer [1].

Unfortunately, the patient developed severe acute chest syndrome during the second cycle following the trastuzumab infusion requiring ICU admission; therefore, the anti-HER2 monoclonal antibody treatment was permanently discontinued. However, the patient successfully completed her paclitaxel chemotherapy cycles as planned.

Furthermore, unlike trastuzumab, the patient tolerated lapatinib — a tyrosine kinase inhibitor against the cytoplasmic domain of HER2 — without any serious complications.

Conclusion: Anti-HER 2 monoclonal antibodies namely Trastuzumab and pertuzumab can precipitate acute chest syndrome in SCD patients with breast cancer.

Keywords: Breast cancer, trastuzumab, sickle cell anemia, chemotherapy, human epidermal growth factor receptors


How to Cite

Al-Zaman, E., Al-Zaman, A. S., & Al-Zaman , Y. (2023). Breast Cancer in SCD Patient: A Case Report and Literature Review. Asian Journal of Medical Case Reports, 5(1), 15–19. Retrieved from https://globalpresshub.com/index.php/AJMCR/article/view/1814

Downloads

Download data is not yet available.

References

Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. Journal of Clinical Oncology. 2008;26(10):1642-9.

Dawkins FW, Kim KS, Squires RS, Chisholm R, Kark JA, Perlin E, Castro O. Cancer incidence rate and mortality rate in sickle cell disease patients at Howard University Hospital: 1986–1995. American journal of hematology. 1997;55(4):188-92.

Schultz WH, Ware RE. Malignancy in patients with sickle cell disease. American journal of hematology. 2003;74(4):249-53.

Al Zaman AS. Breast cancer in patients with sickle cell disease can be treated safely with weekly paclitaxel. Saudi Medical Journal. 2013;34(2):199-201.

Yanni E, Grosse SD, Yang Q, Olney RS. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. The Journal of pediatrics. 2009;154(4):541-5.

Swede H, Andemariam B, Gregorio DI, Jones BA, Braithwaite D, Rohan TE, Stevens RG. Adverse events in cancer patients with sickle cell trait or disease. Genetics in medicine. 2015;17(3):237-41.

Swede H, Andemariam B, Gregorio DI, Jones BA, Braithwaite D, Rohan TE, Stevens RG. Adverse events in cancer patients with sickle cell trait or disease. Genetics in medicine. 2015;17(3):237-41.

Wilson NM, Espirito JL, Valero V, Pusztai L. Paclitaxel-induced sickle cell crisis. American Journal of Health-System Pharmacy. 2008;65(14):1333-6.

Johnston SR, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, Kenny S. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor–positive metastatic breast cancer: ALTERNATIVE. Journal of Clinical Oncology. 2018;36(8): 741.